 | |
| Clinical data | |
|---|---|
| Other names | TRV-734 |
| Routes of administration | Oral[1][2][3] |
| Drug class | μ-Opioid receptorbiased agonist;Analgesic |
| Pharmacokinetic data | |
| Eliminationhalf-life | 1.9–2.5 hours[3] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| Chemical and physical data | |
| Formula | C22H28FN3O |
| Molar mass | 369.484 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
TRV734 is adrug developed byTrevena, Inc. which acts as abiased agonist at theμ-opioid receptor,selective for activation of theG proteinsignaling pathway overβ-arrestin 2 recruitment. It is closely related tooliceridine (TRV130) and has a similar pharmacological profile, but unlike oliceridine which has to beinjected, TRV734 is suitable to be administeredorally.[2][3] The drug reachedphase 2clinical trials for treatment ofpain but was discontinued for this indication.[1][4] It is also under development for treatment ofopioid-related disorders, in association with theNational Institute on Drug Abuse (NIDA) and having reachedphase 1 trials for this use, but no recent development has been reported.[1][4]
